ISO - ISO STOCK NEWS

IsoPlexis announced preliminary unaudited revenue for 2021, projected between $17.0 million and $17.2 million, reflecting a growth of 64% to 66% from $10.4 million in 2020. The company placed 98 new instruments in 2021, totaling 209 instruments since launch. IsoPlexis reported that 67% of US cancer centers and all top 15 pharmaceutical companies now utilize its platform. The new Superhuman Cell Library aims to enhance understanding of disease responses, furthering therapeutic insights. Full results are expected in late February 2022.

IsoPlexis (NASDAQ: ISO) announced it will present data from its IsoLight® platform at the 63rd American Society of Hematology (ASH) conference in Atlanta, Georgia, from December 11-13, 2021. The presentation will discuss leveraging functional 'superhero' cells to enhance cell and immune therapies, focusing on optimizing CAR-T manufacturing and clinical immunotherapies for hematologic malignancies. The talk will occur on December 11, 1:30 PM - 1:45 PM ET in Theater 5.

IsoPlexis (NASDAQ: ISO) has announced key appointments to its leadership team: Richard Rew as Senior VP, General Counsel, Raj Khakhar as VP of Finance, and Manny Resendes as Global Controller. These hires are expected to enhance the company's financial and legal capabilities as IsoPlexis aims for accelerated growth in the life sciences sector. Rew, Khakhar, and Resendes bring over 15 years, 20 years, and 20 years of industry experience respectively, from firms such as Luminex and Thermo Fisher Scientific, which aligns with IsoPlexis’ strategic objectives.

IsoPlexis Corporation (Nasdaq: ISO), a leader in functional single-cell proteomics, will participate virtually in the Evercore ISI 4th Annual HealthCONx Conference on December 1 at 6:40 a.m. Pacific Time. A live and archived webcast of the management's fireside chat can be accessed on the company's website. IsoPlexis is recognized for its innovative approach to identifying proteomically active single cells, aiding researchers in developing precise therapies. Its platform is utilized by leading pharmaceutical companies and comprehensive cancer centers worldwide.

IsoPlexis Corporation (NASDAQ: ISO) announced the publication of two clinical studies in Nature Medicine showcasing the effectiveness of its single-cell proteomic platform in predicting the potency of CAR-T cells and tumor-infiltrating lymphocytes (TILs) in cancer treatments. The studies highlight the platform's ability to assess early indicators of response in cell therapies, enhancing understanding of immune drug functionality. Additionally, IsoPlexis expanded its functional cell library to include various engineered cell types, supporting advancements in the growing cell therapy market.

IsoPlexis (NASDAQ: ISO) announced the addition of Michelle Reid, Ph.D. as VP of Service and Support, and Anthony Catalano as Senior VP of Operations. These strategic appointments aim to enhance operational excellence and customer support as the company focuses on global expansion. Reid brings over 20 years of experience in customer experience for molecular products, while Catalano has extensive operations expertise from PerkinElmer. CEO Sean Mackay highlighted the importance of these roles in driving innovation and addressing customer needs in the proteomics market.

IsoPlexis Corporation (Nasdaq: ISO) reported a 28% increase in Q3 2021 revenue, totaling $4.2 million, compared to Q3 2020. Year-to-date revenue reached $11.7 million, reflecting a 68% growth. However, operating loss surged to $19.9 million, up from $6.3 million the previous year, while net loss increased to $20.2 million. The company completed an IPO in October 2021, raising $111 million. IsoPlexis anticipates full-year revenue growth of at least 61% compared to 2020, driven by new product innovations.

IsoPlexis Corporation (NASDAQ: ISO) announced that it will present data at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 11, 2021, in Washington, DC. The presentation will focus on the use of its new Duomic platform, which combines single-cell proteomics and transcriptomics to identify powerful "superhero cells" critical for effective immune therapies. Attendees can engage with the IsoPlexis platform at Booth #7 on November 12 and 13. This event highlights advancements in CAR-T studies, checkpoint inhibitor studies, and immune therapy discovery.

IsoPlexis Corporation (Nasdaq: ISO) announced it will report its third-quarter financial results on November 10, 2021, before market open. A conference call will follow at 5:30 a.m. PT / 8:30 a.m. ET, which will be webcast on the company's website. IsoPlexis focuses on single-cell proteomics to aid in developing personalized therapeutics. Its technology is utilized by top pharmaceutical companies and cancer centers for complex diseases.